Industry News

  • ILife Discoveries, genetics and genomics company has introduced a new gene test in India. This will help oncologists get a deeper insight into tumors. The new MammaPrint & Blueprint test is able to analyse molecular subtypes of the cancer, risk of recurrence of early stage cancer, thereby enabling medical oncologists to take informed decisions on the course of treatment. For millions of breast cancer patients in India, the twin technologies are advancements that can shed new light on whether treatment is possible without undergoing the harsh chemotherapy process.

  • The US FDA has granted approval to Cipla's Lopinavir, Ritonavir (LPV/r) 40mg/ 10 mg oral pellets for paediatric specific treatment of HIV in infants. Cipla was working for many years in collaboration with Diana Gibb, professor of epidemiology, senior programme leader and honorary consultant paediatrician at Medical Research Council Clinical Trials Unit at UCL (University College London) towards development of this novel child-friendly formulation which has been approved by US FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. This product is a first step in making accessible more modern and appropriately formulated treatment available to the most vulnerable of HIV patients – young children.

  • BioCision is a leading supplier of cell cryopreservation products, systems, and solutions announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), for development of a cell thawing solution based on BioCision’s proprietary ThawSTAR technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

  • Mylan N.V., a global pharmaceutical company,  launched guanfacine extended-release tablets, 1 mg, 2 mg, 3 mg, and 4 mg, which is the generic version of Shire's Intuniv tablets in US markets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.The company received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

  • AstraZeneca Pharma India Limited and Dr. Reddy’s Laboratories Ltd. Collaborate to marketing  for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and marketed in the Indian market.

  • OPTM Healthcare, with its ever evolving streak of innovating absolutely natural treatments with 100% recovery, has devised a remarkable alternative to treat osteoarthritis with phytomedicines. Its team of professional physicians has scientifically developed plant-originated Indian herbal medicines, known as phytomedicines, to use as an excellent cure for this disease along with many others.

  • (NewsVoir); Abbott, India’s leading multinational healthcare company announced the launch of ‘LiverHealth’, a new initiative aimed at providing access to an easy diagnosis of liver health and raising awareness of Hepatitis C (an infectious disease affecting the liver, caused by the Hepatitis C Virus) condition in India.

    [adsense:336x280:8701650588]

  • (NewsVoir); With an aim to increase awareness on environmental issues and the citizen’s responsibilities towards it, Ahmedabad based Cadila Pharmaceuticals Ltd is going to celebrate ‘World Environment Day’ in a unique way. The Company will launch ‘Consume with Care and Sustainable Production’ awareness drive to conserve natural resources that are fast depleting. Other activities like poster competition, essay contest, quiz and slogan contest, based on the theme of ‘Sustainability and Consumption’ will also be organized at company’s various locations.

  • Siemens Healthcare planning to introduce the Magnetom Terra 7 Tesla MRI system to convert cutting-edge MRI research results into clinical application. This translation will allow user in less than ten minutes.  New 7 Tesla MRI system provides the whole range of cutting-edge 7 Tesla research functionalities, and is based on the latest software platform syngo MR E11, identical to Siemens’ latest flagship 3 Tesla MRI systems, to enable consistent usability and protocol exchange. It is the world’s first ultra-high field research system ready for future clinical use with planned CE and FDA authorization to market for selected neurological and musculoskeletal MR imaging applications.

Subscribe to Industry News